Global Information
회사소개 | 문의 | 위시리스트

세계의 알츠하이머병 치료제 및 진단약 시장 예측

Global Alzheimer´s Disease Therapeutics and Diagnostics Market Forecast 2020-2028

리서치사 Inkwood Research
발행일 2020년 01월 상품 코드 628603
페이지 정보 영문 214 Pages
가격
US $ 2,500 ₩ 3,044,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 되지 않으며, 인쇄 또한 불가능합니다.
US $ 3,000 ₩ 3,652,000 PDF (Multi User License) help
동일 사업장(소재지) 내 5명까지 이용가능한 라이센스입니다. PDF 파일은 Copy & Paste가 되지 않습니다. 인쇄는 1명당 1회에 한해 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,500 ₩ 5,479,000 PDF (Enterprisewide License) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 알츠하이머병 치료제 및 진단약 시장 예측 Global Alzheimer´s Disease Therapeutics and Diagnostics Market Forecast 2020-2028
발행일 : 2020년 01월 페이지 정보 : 영문 214 Pages

세계의 알츠하이머병(AD: Alzheimer's Disease) 치료제 및 진단약 시장 전망에 대해 분석했으며, 제품 및 기술 개요, 시장의 기본 구조, 주요 성장 촉진요인 및 억제요인, 시장 전체 및 제품별·지역별 시장 동향 전망(향후 10년간), 관련 시장과의 연관성, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

제1장 조사 범위와 분석 방법

제2장 주요 요약

  • 시장 규모와 추정
  • 시장 개요

제3장 시장 역학

  • 상위 시장 분석 : 알츠하이머병 치료제 및 진단약 시장
  • 시장 정의
  • 주요 시장 성장 촉진요인
  • 주요 시장 성장 억제요인

제4장 주요 지표

  • Porter's Five Forces 분석
    • 신규 참여업체의 위협
    • 대체 제품의 위협
    • 구매자의 협상력
    • 공급업체의 협상력
    • 경쟁사와의 경쟁
  • 주요 구매 기준
    • 가격
    • 효능
    • 안전성
  • 알츠하이머병 치료제 및 진단약 시장 역학 분석
  • 공급망 분석
    • 기업 인수합병(M&A)
    • 원재료
    • 제조
    • 도매업체
    • 최종사용자
  • 알츠하이머병의 단계와 증상
  • 시장 기회 매트릭스
  • 벤더 상황
  • 주요 투자 인사이트

제5장 치료제 및 진단약별 시장

  • 치료제
    • 치료제 : 약제 종류별(출시 약제/파이프라인 약제)
    • 치료제 : 병기별
    • 치료제 : 제네릭 의약품/브랜드 의약품
  • 진단약
    • 요추 기능 검사
    • PET(양전자 방출 단층촬영)
    • 뇌파계
    • MRI
    • CT
    • 기타 진단

제6장 지역별 분석

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 러시아
    • 벨기에
    • 폴란드
    • 기타
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 호주 및 뉴질랜드
    • 한국
    • 태국
    • 인도네시아
    • 베트남
    • 기타
  • 기타 국가(RoW)
    • 중남미
    • 중동 및 아프리카

제7장 기업 개요

  • ALLERGAN PLC
  • AMARANTUS BIOSCIENCE HOLDINGS INC.
  • BAXTER INTERNATIONAL INC.
  • BIOGEN INC.
  • COGNOPTIX, INC.
  • Eisai Co., Ltd.
  • ELI LILLY & COMPANY
  • F. HOFFMANN-LA ROCHE
  • GE HEALTHCARE
  • JOHNSON & JOHNSON
  • LUPIN LIMITED
  • MERCK & CO. INC.
  • NOVARTIS AG
  • PFIZER INC.
  • SUN PHARMACEUTICALS INDUSTRIES LTD.
LSH 20.01.31

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - ALZHEIMER'S DISEASE AND THERAPEUTICS
  • TABLE 2: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 3: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 4: GLOBAL THERAPEUTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 5: GLOBAL THERAPEUTICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 6: GLOBAL THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 7: GLOBAL THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 8: GLOBAL MARKETED DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 9: GLOBAL MARKETED DRUGS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 10: GLOBAL PIPELINE DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 11: GLOBAL PIPELINE DRUGS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 12: GLOBAL THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 13: GLOBAL THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 14: GLOBAL LATE STAGE: SEVERE AD MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 15: GLOBAL LATE STAGE: SEVERE AD MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 16: GLOBAL EARLY/MIDDLE STAGE: MILD TO MODERATE AD MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 17: GLOBAL EARLY/MIDDLE STAGE: MILD TO MODERATE AD MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 18: GLOBAL PRODROMAL STAGE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 19: GLOBAL PRODROMAL STAGE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 20: GLOBAL THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 21: GLOBAL THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 22: GLOBAL BRANDED MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 23: GLOBAL BRANDED MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 24: GLOBAL GENERIC MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 25: GLOBAL GENERIC MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 26: GLOBAL DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 27: GLOBAL DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 28: GLOBAL DIAGNOSTICS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 29: GLOBAL DIAGNOSTICS MARKET, BY TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 30: GLOBAL LUMBAR PUNCTURE TEST MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 31: GLOBAL LUMBAR PUNCTURE TEST MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 32: GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 33: GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 34: GLOBAL ELECTROENCEPHALOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 35: GLOBAL ELECTROENCEPHALOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 36: GLOBAL MAGNETIC RESONANCE IMAGING MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 37: GLOBAL MAGNETIC RESONANCE IMAGING MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 38: GLOBAL COMPUTED TOMOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 39: GLOBAL COMPUTED TOMOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 40: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 41: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 42: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 43: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 44: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 45: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 46: EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 47: EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 48: ASIA PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 49: ASIA PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 50: REST OF WORLD ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 51: REST OF WORLD ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: PIPELINE DRUGS RELATED TO ALZHEIMER'S DISEASE
  • FIGURE 2: COSTS OF CARE FOR PEOPLE WITH ALZHEIMER'S AND OTHER DEMENTIAS, 2017 ($ BILLION)
  • FIGURE 3: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 4: SUPPLY CHAIN ANALYSIS
  • FIGURE 5: OPPORTUNITY MATRIX
  • FIGURE 6: VENDOR LANDSCAPE
  • FIGURE 7: KEY INVESTMENT INSIGHTS
  • FIGURE 8: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2020-2028 ($ MILLION)
  • FIGURE 9: GLOBAL THERAPEUTICS MARKET, BY MARKETED DRUGS, 2020-2028 ($ MILLION)
  • FIGURE 10: GLOBAL THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2020-2028 ($ MILLION)
  • FIGURE 11: GLOBAL THERAPEUTICS MARKET, BY LATE STAGE: SEVERE AD, 2020-2028 ($ MILLION)
  • FIGURE 12: GLOBAL THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2020-2028 ($ MILLION)
  • FIGURE 13: GLOBAL THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2020-2028 ($ MILLION)
  • FIGURE 14: GLOBAL THERAPEUTICS MARKET, BY BRANDED, 2020-2028 ($ MILLION)
  • FIGURE 15: GLOBAL THERAPEUTICS MARKET, BY GENERIC, 2020-2028 ($ MILLION)
  • FIGURE 16: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2020-2028 ($ MILLION)
  • FIGURE 17: GLOBAL DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2020-2028 ($ MILLION)
  • FIGURE 18: GLOBAL DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2020-2028 ($ MILLION)
  • FIGURE 19: GLOBAL DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2020-2028 ($ MILLION)
  • FIGURE 20: GLOBAL DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2020-2028 ($ MILLION)
  • FIGURE 21: GLOBAL DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2020-2028 ($ MILLION)
  • FIGURE 22: GLOBAL DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2020-2028 ($ MILLION)
  • FIGURE 23: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 24: THE UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 25: CANADA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 26: EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 27: THE UNITED KINGDOM ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 28: FRANCE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 29: GERMANY ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 30: ITALY ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 31: RUSSIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 32: BELGIUM ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 33: POLAND ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 34: REST OF EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 35: ASIA PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 36: CHINA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 37: INDIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 38: JAPAN ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 39: AUSTRALIA & NEW ZEALAND ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 40: SOUTH KOREA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 41: THAILAND ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 42: INDONESIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 43: VIETNAM ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 44: REST OF ASIA PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 45: REST OF WORLD ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 46: LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 47: MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)

KEY FINDINGS

The global Alzheimer's therapeutics and diagnostics market is estimated to record a CAGR of 5.21% during the projected period of 2020-2028. The rising geriatric population, an increase in the pervasiveness of Alzheimers disease, research and development of novel diagnostics technologies, and drugs are the factors predicted to influence market growth.

MARKET INSIGHTS

The scope of the therapeutic market involves segments such as drug, disease, stage, generic, and branded. The diagnostics market consists of diagnostics biomarkers used for Alzheimer's disease. The growing investments in biomarkers for the development of drugs and early detection of Alzheimers disease can lead to higher adoption rates of biomarker-based diagnostics and the development of new therapeutics, boosting the market growth. For example, in 2018, Duke University conducted research programs and clinical trials for the development of blood biomarkers of Alzheimers disease. Intensive research is going on in the field of drugs and medicines that are used for the treatment of Alzheimers disease. The adoption rate of Alzheimer's drugs and biomarkers is high due to the increasing prevalence of the disease worldwide. The market faces the challenges of failure in later stages of clinical trials, strict government regulations for developing and commercializing drugs, and expensive therapies used for Alzheimer's treatment.

REGIONAL INSIGHTS

The global market of Alzheimer's disease therapeutics and diagnostics is analyzed by analyzing the regions of North America, Europe, Asia Pacific, and the Rest of the World. The region is also estimated to garner the largest market share during the forecast period. This is attributed to the growing geriatric population, high spending on healthcare, and the pervasiveness of Alzheimer's disease across the US. The Asia Pacific market region is projected to record the fastest growth rate during the forecasted period.

COMPETITIVE INSIGHTS

The global Alzheimer's disease therapeutics and diagnostics market's competitive nature is fueled by the large presence of major industry players. Some of the well-known companies in the market include, GE Healthcare, Johnson & Johnson, Novartis AG, Sun Pharmaceuticals Industries Ltd., Pfizer Inc., etc.

Our report offerings include:

Explore key findings of the overall market

Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)

Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions

Market Segmentation cater to a thorough assessment of key segments with their market estimations

Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.

Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.

Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARIES

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. PARENT MARKET ANALYSIS: ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
  • 3.2. MARKET DEFINITION
  • 3.3. KEY DRIVERS
    • 3.3.1. GROWING GERIATRIC POPULATION
    • 3.3.2. RISE IN THE PERVASIVENESS OF ALZHEIMER'S DISEASE
    • 3.3.3. EMERGING NOVEL DIAGNOSTIC TECHNOLOGIES
    • 3.3.4. INCREASING PIPELINE DRUGS
  • 3.4. KEY RESTRAINTS
    • 3.4.1. FAILURE OF THE LATE-STAGE DRUGS
    • 3.4.2. STRINGENT GOVERNMENT REGULATIONS
    • 3.4.3. HIGH COST OF THERAPIES USED FOR THE TREATMENT OF ALZHEIMER'S DISEASE

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCE ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. KEY BUYING CRITERIA
    • 4.2.1. PRICE
    • 4.2.2. EFFICIENCY
    • 4.2.3. SAFETY
  • 4.3. ETYMOLOGY OF ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
  • 4.4. SUPPLY CHAIN ANALYSIS
    • 4.4.1. RESEARCH AND DEVELOPMENT
    • 4.4.2. RAW MATERIALS
    • 4.4.3. MANUFACTURING
    • 4.4.4. WHOLESALERS
    • 4.4.5. END USER
  • 4.5. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE
  • 4.6. OPPORTUNITY MATRIX
  • 4.7. VENDOR LANDSCAPE
  • 4.8. KEY INVESTMENT INSIGHTS

5. MARKET BY THERAPEUTICS AND DIAGNOSTICS

  • 5.1. THERAPEUTICS
    • 5.1.1. THERAPEUTICS BY DRUGS
      • 5.1.1.1. MARKETED DRUGS
      • 5.1.1.2. PIPELINE DRUGS
    • 5.1.2. THERAPEUTICS BY DISEASE STAGE
      • 5.1.2.1. LATE STAGE: SEVERE AD
      • 5.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD
      • 5.1.2.3. PRODROMAL STAGE
    • 5.1.3. THERAPEUTICS BY GENERIC AND BRANDED
      • 5.1.3.1. BRANDED
      • 5.1.3.2. GENERIC
  • 5.2. DIAGNOSTICS
    • 5.2.1. LUMBAR PUNCTURE TEST
    • 5.2.2. POSITRON EMISSION TOMOGRAPHY
    • 5.2.3. ELECTROENCEPHALOGRAPHY
    • 5.2.4. MAGNETIC RESONANCE IMAGING
    • 5.2.5. COMPUTED TOMOGRAPHY
    • 5.2.6. OTHER DIAGNOSTICS

6. GEOGRAPHICAL ANALYSIS

  • 6.1. NORTH AMERICA
    • 6.1.1. THE UNITED STATES
    • 6.1.2. CANADA
  • 6.2. EUROPE
    • 6.2.1. THE UNITED KINGDOM
    • 6.2.2. FRANCE
    • 6.2.3. GERMANY
    • 6.2.4. ITALY
    • 6.2.5. RUSSIA
    • 6.2.6. BELGIUM
    • 6.2.7. POLAND
    • 6.2.8. REST OF EUROPE
  • 6.3. ASIA PACIFIC
    • 6.3.1. CHINA
    • 6.3.2. INDIA
    • 6.3.3. JAPAN
    • 6.3.4. AUSTRALIA & NEW ZEALAND
    • 6.3.5. SOUTH KOREA
    • 6.3.6. THAILAND
    • 6.3.7. INDONESIA
    • 6.3.8. VIETNAM
    • 6.3.9. REST OF ASIA PACIFIC
  • 6.4. REST OF WORLD
    • 6.4.1. LATIN AMERICA
    • 6.4.2. MIDDLE EAST & AFRICA

7. COMPANY PROFILES

  • 7.1. ALLERGAN PLC
  • 7.2. AMARANTUS BIOSCIENCE HOLDINGS INC.
  • 7.3. BAXTER INTERNATIONAL INC.
  • 7.4. BIOGEN INC.
  • 7.5. COGNOPTIX, INC.
  • 7.6. EISAI CO. LTD
  • 7.7. ELI LILLY & COMPANY
  • 7.8. F. HOFFMANN-LA ROCHE
  • 7.9. GE HEALTHCARE
  • 7.10. JOHNSON & JOHNSON
  • 7.11. LUPIN LIMITED
  • 7.12. MERCK & CO. INC.
  • 7.13. NOVARTIS AG
  • 7.14. PFIZER INC.
  • 7.15. SUN PHARMACEUTICALS INDUSTRIES LTD.
Back to Top
전화 문의
F A Q